SA
SPRY logo
ARS Pharmaceuticals, Inc.(SPRY)
Updated 3:48 PM ETAbout this dataData status
$3.31▼-0.38 (-10.16%)

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.2 · elevated volatility

Overview →

Consensus

Buy4.00 / 53 ratings · Buy 3

Price vs analyst targets

Revenue and EPS estimates

ReportedConsensus estimates
Fiscal periodFY2023Dec '23FY2024Dec '24FY2025Dec '25FY2026Dec '26FY2027Dec '27FY2028Dec '28FY2029Dec '29FY2030Dec '30
Revenue (M)0.08.584.3120.4165.4245.6307.1353.1
Growth YoY−99.6%+84700.0%+894.0%+42.9%+37.4%+48.5%+25.0%+15.0%
High estimate0.014.7–121.6186.5288.9341.4392.5
Low estimate0.02.3–119.3144.3210.3275.8317.1
Analysts23–33312
EPS, adjusted−0.570.08−1.75−1.81−0.74−0.190.140.19
Growth YoYn/mn/m−2287.5%n/mn/mn/mn/m+39.0%
High estimate–––−1.74−0.640.210.160.22
Low estimate–––−1.89−0.87−0.620.120.16
Analysts–––33311

Consensus mean of analyst estimates. EPS is adjusted (street) EPS, the basis analysts forecast; annual actuals are the sum of the four reported quarters. Growth compares with the same period a year earlier; n/m where the prior period was a loss.

Brokers

4 firms active in the last 12 months
FirmAnalystRatingPrev ratingTargetPrev targetChgUpsideDate
Cantor Fitzgerald–OverweightOverweight––––Nov 6
Raymond James–OutperformStrong Buy––––Nov 6
Leerink PartnersRoanna RuizOutperform · Aug 2026Outperform$15.00$26.00−42%+365%Sep 8
Northland Securities–––$25.00––+675%Apr 9

Latest analyst action Page refreshed hourly; analyst feeds refreshed dailyAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.